Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 425 | 24 | 392 |
| Samples | 206 | 12 | 189 |
| Peptides | 162 | 10 | 153 |
Function
BORCS8-MEF2B · BORCS8-MEF2B readthrough
This gene represents numerous read-through transcripts that span GeneID:729991 and 100271849. Many read-through transcripts are predicted to be nonsense-mediated decay (NMD) candidates, and are thought to be non-coding. Some transcripts are predicted to be capable of translation reinitiation at a downstream AUG, resulting in expression of at least one isoform of myocyte enhancer factor 2B (MEF2B) from this read-through locus. At least one additional MEF2B variant and isoform can be expressed from a downstream promoter, and is annotated on GeneID:100271849. [provided by RefSeq, Oct 2010].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 146 amino-acid changes on canonical ENST00000444486 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in BORCS8-MEF2B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in BORCS8-MEF2B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 3/42 7% | 8/612 1% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 37/2534 1% |
| Burkitts Lymphoma | 0/32 0% | 2/196 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Ovarian Carcinoma | 0/109 0% | 8/998 1% |
| Melanoma | 0/210 0% | 15/1899 1% |
| Gastric Carcinoma | 0/74 0% | 13/1809 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 4/1390 0% |
| Hepatocellular Carcinoma | 1/46 2% | 11/2210 0% |
| Other Solid Cancers | 0/94 0% | 8/1515 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 8/1592 0% |
| Osteosarcoma | 0/45 0% | 1/166 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 4/810 0% |
| Head and Neck Carcinoma | 0/85 0% | 7/1574 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 11/2550 0% |
| Colorectal Carcinoma | 1/143 1% | 13/3239 0% |
| Bladder Carcinoma | 0/58 0% | 4/956 0% |
| Other Blood Cancers | 0/61 0% | 11/2725 0% |
| Neuroendocrine Tumour | 0/154 0% | 2/577 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| Breast Carcinoma | 0/144 0% | 6/3264 0% |
| Glioma | 0/52 0% | 4/2127 0% |
| Kidney Carcinoma | 0/85 0% | 3/1862 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Neuroblastoma | 0/87 0% | 1/1331 0% |
| Pancreatic Carcinoma | 0/89 0% | 1/1611 0% |
| Prostate Carcinoma | 0/13 0% | 1/2105 0% |
Mutation Distribution
Where BORCS8-MEF2B is mutated · all tissues, split by cell line vs tissue
How many mutations in BORCS8-MEF2B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
Mutations
All 425 mutations in BORCS8-MEF2B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|